Select a State

Global health R&D delivers for Texas

US government investment in global health R&D has delivered

$201.6 million
to Texas research institutions
3,100+ new jobs
for Texas
4491

Neglected diseases in Texas

Chikungunya cases
201
Dengue cases
248
HIV diagnoses
39274
Malaria cases
676
Tuberculosis cases
11998
West Nile cases
3370
Zika cases
364

Texas

--

Texas's top USG-funded global health R&D institutions

University of Texas Medical Branch at Galveston
$ 36.9 million
Texas A&M University (including Engineering Experiment Station)
$ 32.6 million
University of Texas at Dallas (including University of Texas Southwestern Medical Center at Dallas)
$ 25.5 million
University of Texas at San Antonio (including University of Texas Health Science Center San Antonio)
$ 18.9 million
Texas Biomedical Research Institute
$ 15 million
Southwest Foundation for Biomedical Research
$ 11.5 million
University of Texas at El Paso
$ 10.6 million
University of Texas at Austin
$ 10 million
Texas Tech University
$ 8.4 million
Baylor College of Medicine
$ 7.1 million

Texas industry in global health R&D

AI Biosciences
Location(s):
College Station
AM Biotechnologies
Location(s):
Houston
Bayer
Location(s):
Pasadena
Beckman Coulter
Location(s):
Irving
Celgene
Location(s):
Dallas
Charles River Laboratories
Location(s):
Houston
Innovar Scientific
Location(s):
Lucas
J-LABS
Location(s):
Houston
Luminex
Location(s):
Austin
Novartis
Location(s):
Forth Worth, Houston
item[company]
Location(s):
Dallas
item[company]
Location(s):
San Marcos
item[company]
Location(s):
Houston
item[company]
Location(s):
Austin
item[company]
Location(s):
Austin, Houston, San Antonio

Texas's top areas of global health R&D by USG funding

9.6%
HIV/AIDS
9.4%
Malaria
29.9%
Tuberculosis
11.5%
Diarrheal diseases
4.1%
Ebola/viral hemorrhagic fevers
2.8%
Salmonella infections
29.4%
Neglected tropical diseases
Buruli ulcer
Dengue
Helminths
Kinetoplastids
Trachoma
3.3%
Other
Bacteria pneumonia & meningitis
Non-allocable

Global health R&D at work in Texas

University of Texas Medical Branch at Galveston is using a computer-based discovery approach to identify potential new drugs for dengue and similar diseases for which there are currently no effective treatments. Almost half of the world’s population is at risk for dengue, a mosquito-borne infection related to hepatitis C, West Nile, and yellow fever. New treatments could have a huge impact on improving health worldwide.

Footnotes